Navigation Links
Yale test detects early stage ovarian cancer with 99 percent accuracy
Date:2/12/2008

Researchers at Yale School of Medicine have developed a blood test with enough sensitivity and specificity to detect early stage ovarian cancer with 99 percent accuracy.

Results of this new study are published in the February 15 issue of the journal Clinical Cancer Research. The results build on work done by the same Yale group in 2005 showing 95 percent effectiveness of a blood test using four proteins.

The ability to recognize almost 100 percent of new tumors will have a major impact on the high death rates of this cancer, said Mor. We hope this test will become the standard of care for women having routine examinations.

Epithelial ovarian cancer is the leading cause of gynecologic cancer deaths in the United States and three times more lethal than breast cancer. It is usually not diagnosed until its advanced stages and has come to be known as the silent killer.

This new phase II clinical trial led by Gil Mor, M.D., associate professor in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale, included 500 patients; 350 healthy controls and 150 ovarian cancer patients. Mor and colleagues validated the previous research and used a new platform called multiplex technology to simplify the test into one single reaction using very small amounts of serum from the blood. The new platform uses six protein biomarkers instead of four, increasing the specificity of the test from 95 to 99.4 percent. The team looked for the presence of specific proteins and quantified the concentration of those proteins in the blood.

The Early Detection Research Network (EDRN) of the National Cancer Institute (NCI) independently evaluated the results of the test.

This is the most sensitive and specific test currently available, said Mor. Previous tests recognized 15 to 20 percent of new tumors. Proteins from the tumors were the only biomarkers used to test for ovarian cancer. That is okay when you have big masses of tumors, but it is not applicable in very early phases of the tumor. Testing the proteins produced by the body in response to the presence of the tumor as well as the proteins the tumors produce, helped us to create a unique picture that can detect early ovarian cancer.

Mor and colleagues have begun a phase III evaluation in a multi-center clinical trial. In collaboration with EDRN/NCI and Laboratories Corporation of America (LabCorp), they are testing close to 2,000 patients.

The test is available at Yale through the Discovery to Cure program. Yale has licensed the test to three companies: Lab Corp in the United States, Teva in Israel and SurExam in China.


'/>"/>

Contact: Karen N. Peart
karen.peart@yale.edu
203-432-1326
Yale University
Source:Eurekalert  

Related medicine news :

1. Test Detects Sensitivity to HIV Drug
2. McMaster test detects the most prevalent respiratory viruses
3. CT colonography detects wide-range of extracolonic abnormalities in elderly patients
4. Blood protein detects lung cancer, even at earliest stage
5. New technique detects specific chromosomal damage, may indicate lung cancer risk
6. New Survey Suggests Confusion, Lack of Awareness About Heart Failure Could Be Preventing Critical Early Detection and Treatment
7. JCI online early table of contents: Feb. 7, 2008
8. New study suggests link between environmental toxins and early onset puberty in girls
9. A Reminder to Parents: Early Dental Visits Essential to Childrens Health
10. Rheumatoid arthritis sends many into early retirement
11. Early detection critical in treating pediatric thyroid cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Yale test detects early stage ovarian cancer with 99 percent accuracy
(Date:5/27/2016)... ... 27, 2016 , ... Aimed at nurses and employees in the health care ... leaders in the nursing and health care industry. It also provides insight to the ... University. , As the nursing industry is coming out of one of the ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports hinting at a ... to wait until March 2017 for an interest rate increase, according to Rajeev Dhawan ... Business. , “The Federal Open Market Committee (FOMC) dot charts are of interest to ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot Corporation, Pfizer, and ... according to court documents and SEC filings. A jury has returned a ... American Optical Corporation, Case No. BC588866, Los Angeles County, California. The jury awarded ...
(Date:5/26/2016)... , ... May 26, 2016 , ... Connor Sports, ... basketball as a partner for the Tamika Catchings Legacy Tour that will ... industry leader in hardwood basketball surfaces in all forms and levels of the game, ...
(Date:5/26/2016)... ... 2016 , ... Cardiac arrhythmia is a common complication following ... survival, reports a team of UPMC researchers in the largest study of its ... Thoracic and Cardiovascular Surgery, provide critical information that will hopefully lead to better ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , Deutschland und GERMANTOWN, Maryland ... Zusammenarbeit mit Therawis bedient ... bei Brustkrebs   QIAGEN N.V. (NASDAQ: ... gab heute bekannt, eine Lizenz- und Entwicklungsvereinbarung mit ... Assays für die Onkologie eingegangen zu sein. Ein ...
(Date:5/25/2016)... May 25, 2016 As illustrated ... earlier this month, the numbers and momentum of cannabis ... climb into the billions, more research and development push ... Edition State of Legal Marijuana Markets Report  from from ... firm, much of the increase in sector is attributed ...
(Date:5/25/2016)... , May 25, 2016 ... H1 2016"market research report that provides an overview ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ...
Breaking Medicine Technology: